Search Results

Renal Research Institute, a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, announced together with the Karolinska Institutet a joint symposium, “Prevention of CKD progression: the impact of new therapeutics.” The Karolinska Institutet is one of the world’s leading medical universities.

Alzheon, Inc. announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for the future, at the Karolinska Institute in Stockholm, Sweden from January 18-19.

XNK Therapeutics AB announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia.

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is excited to announce a new collaboration with Associate Professor Jonas Fuxe and his research team at the Karolinska Institute (KI) in Stockholm, Sweden, to characterize the molecular targets of Qu’s SSI therapy at the tissue level that lead to resolution of disease.

Teleflex Incorporated announced that Dr. Magnus Settergren*, Asssociate Professor at the Karolinska Institutet, Interventional Cardiologist at Karolinska University Hospital is scheduled to present at a Teleflex-sponsored Training Pavilion at the Transcatheter Cardiovascular Therapeutics conference.

A MOMENTUM™ Magnetic Particle Imaging (MPI) Scanner by Magnetic Insight has been installed at the Preclinical Imaging Facility at the Karolinska Institutet in Stockholm, Sweden.

Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.